


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Seonyoung Kim et al. Examiner: To Be Assigned  
Serial No.: 09/981,968 Group Art Unit: 1614  
Filed: October 18, 2001 Docket: G&C 130.60-US-U1  
Title: METHODS OF STABILIZING PROTEIN FORMULATION STABILITY  
AND SURFACTANT-STABILIZED INSULIN FORMULATION DERIVED  
THEREFROM

CERTIFICATE OF MAILING OR TRANSMISSION UNDER 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on March 4, 2003.

By:   
Name: William J. Wood

INFORMATION DISCLOSURE STATEMENT (37 C.F.R. §1.97(b))

Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

With regard to the above-identified application, the items of information listed on the enclosed Form 1449 are brought to the attention of the Examiner.

This statement should be considered because it is submitted before the mailing date of a first Office Action on-the-merits. Accordingly, no fee is due for consideration of the items listed on the enclosed Form 1449.

In accordance with 37 C.F.R. §1.98(a)(2), a copy of each document or other information listed on the enclosed Form 1449 is provided.

No representation is made that a reference is "prior art" within the meaning of 35 U.S.C. §§ 102 and 103 and Applicants reserve the right, pursuant to 37 C.F.R. § 1.131 or otherwise, to establish that the reference(s) are not "prior art". Moreover, Applicants do not represent that a reference has been thoroughly reviewed or that any relevance of any portion of a reference is intended.

Consideration of the items listed is respectfully requested. Pursuant to the provisions of M.P.E.P. 609, it is requested that the Examiner return a copy of the attached Form 1449, marked as being considered and initialed by the Examiner, to the undersigned with the next official communication.

Please direct any response or inquiry to the below-signed attorney at (310) 641-8797.

Respectfully submitted,

GATES & COOPER LLP  
Attorneys for Applicant(s)

Howard Hughes Center  
6701 Center Drive West, Suite 1050  
Los Angeles, California 90045  
(310) 641-8797

Date: March 4, 2003

WJW/kmf

By: 

William J. Wood

Reg. No.: 42,236

Form 1449* <b>INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION</b>	Docket Number: G&C 130.60-US-U1	Application Number: 09/981,968
	Applicant: Seonyoung Kim et al.	
	Filing Date: October 18, 2001	Group Art Unit: 1614


U.S. PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	4,439,181	03/27/84	Blackshear et al.			
	<del>4,652,548</del>	<del>03/24/87</del>	<del>Chance et al.</del>			
	4,839,341	06/13/89	Massey et al.			
	4,885,164	12/05/89	Thurrow			
	4,988,675	01/29/91	Froesch et al.			
	5,149,777	09/22/92	Hansen et al.			
	5,474,978	12/12/95	Bakaysa et al.			
	5,514,646	05/07/96	Chance et al.			
	5,527,307	06/18/96	Srisathapat et al.			
	5,569,186	10/29/96	Lord et al.			
	5,637,095	06/10/97	Nason et al.			
	5,641,744	06/24/97	Cooper			
	5,753,681	05/19/98	Fujiwara et al.			
	5,783,556	07/21/98	Clark et al.			
	5,952,297	09/14/99	De Felippis et al.			
	5,958,909	09/28/99	Habener			
	6,034,054	03/07/00	DeFelippis et al.			
	6,133,229	10/17/00	Gibson et al.			
	6,136,784	10/24/00	L'Italien et al.			
	6,153,632	11/28/00	Rieveley			
	6,166,042	12/26/00	Ikeda et al.			
	6,166,043	12/26/00	Ikeda et al.			
	6,169,099	01/02/01	Ikeda et al.			
	6,169,100	01/02/01	Ikeda et al.			
	6,174,856	01/16/01	Langballe et al.			
	6,211,144	04/03/01	Havelund			
	6,268,343	07/31/01	Knudsen et al.			
	US2001/0031726	10/18/01	Van Antwerp et al.			
	6,323,311	11/27/01	Liu et al.			

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.

Form 1449* <b>INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION</b>	Docket Number: G&C 130.60-US-U1	Application Number: 09/981,968
	Applicant: Seonyoung Kim et al.	
	Filing Date: October 18, 2001	Group Art Unit: 1614



FOREIGN PATENTS							
	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	EP 0 726 075 A1	08/14/96	EPO				
	EP 0 925 792 A2	06/30/99	EPO				
	EP 1 090 640 A2	04/11/01	EPO				
	WO 92/20366	11/26/92	PCT				
	WO 96/02270	02/01/96	PCT				
	WO 98/56406	12/17/98	PCT				
	WO 98/57636	12/23/98	PCT				
	WO 99/43705	09/02/99	PCT				
	WO 99/64589	12/16/99	PCT				
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
	Ahren et al., "Effects of Glucagon-Like Peptide-1 on Islet Function and Insulin Sensitivity in Noninsulin-Dependent Diabetes Mellitus," J. of Clin. Endocrinology and Metabolism, 1997, 82(2):473-478						
	Brange et al., "Chemical Stability of Insulin: 3. Influence of Excipients, Formulation, and pH," Acta Pharmaceutica Nordica, 1992, 4(3): 149-158						
	Gutniak et al., "Antidiabetogenic Effect of Glucagon-Like Peptide-1 (7-36) Amide in Normal Subjects and Patients with Diabetes Mellitus," The New England Journal of Medicine, 1992, 1316-1322						
	Holst, "GLP-1 in NIDDM," Diabetic Med., 1996, (9 suppl. 6), pp. S156-160						
	Jones et al., "Surfactant-Stabilized Protein Formulations," Therapeutic Protein and Peptide Formulations and Delivery, 1997, American Chemical Society Publication, chapter 12, p. 206						
	LeVine, III, "Thioflavine T Interaction with Synthetic Alzheimer's Disease $\beta$ -amyloid Peptides: Detection of Amyloid Aggregation in Solution," Protein Science, 1993, 2: 404-410						
	Mokuda et al., "Plasma Glucose Response After Intravenous Injection of Tolbutamide in Insulin-Treated Type I and Type II Diabetic Patients," Exp. Clin. Endocrinol., 1988, 91(3): 265-270						
	Nielsen et al., "Effect of Environmental Factors on the Kinetics of Insulin Fibril Formation: Elucidation of the Molecular Mechanism," Biochemistry, 2001, 40: 6036-6046						
	Quinn et al., "Minimizing the Aggregation of Neutral Insulin Solutions," Jnl. Of Pharmaceutical Sciences, 1983, 72(12): 1472-1473						
	Ryan et al., "Insulinotropic Hormone Glucagon-Like Peptide-1-(7-37) Appears not to Augment Insulin-Mediated Glucose Uptake in Young Men During Euglycemia," J. of Clin. Endocrinology and Metabolism, 1998, 83(7): 2399-2404						
	Sluzky et al., "Kinetics of Insulin Aggregation in Aqueous Solutions Upon Agitation in the Presence of Hydrophobic Surfaces," Proc. Of Natl. Acad. Sciences, 1991, 88: 9377-9381						
	Toft-Nielsen et al., "The Effect of Glucagon-Like Peptide I (GLP-I) on Glucose Elimination in Healthy Subjects Depends on the Pancreatic Glucoregulatory Hormones," Diabetes, 1996, 45: 552-556						

EXAMINER:	DATE CONSIDERED:
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	